Clinical Trial – Monitoring and Treatment of Relapsed Leukemia – Leukemia

Reuven Schore is running a clinical trial to test drugs called Bortezomib and Pravastatin to treat Leukemia. This study aims to monitor patients for relapse of the leukemia following allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in order to identify patients early in relapse, with a low burden of disease, when interventions may be more successful by monitoring of peripheral blood lineage specific chimerism. Once disease has been confirmed, patients will initiate a novel combination of bortezomib and pravastatin.

The drugs are Bortezomib and Pravastatin.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Actual Study Start Date : May 2015
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : August 2020

Contacts

Contact: Maggie Holly 202-476-5532 mholly@childrensnational.org
Contact: Reuven Schore, MD 202-476-5875 rschore@childrensnational.org

NCT Number

NCT number: NCT02484261

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.